Literature DB >> 5339036

A trial of streptonigrin in the treatment of advanced malignant disease.

G M Smith, J A Gordon, I A Sewell, H Ellis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 5339036      PMCID： PMC2008125          DOI： 10.1038/bjc.1967.32

Source DB:  PubMed          Journal:  Br J Cancer        ISSN： 0007-0920            Impact factor:   7.640


× No keyword cloud information.
  2 in total

1.  Preliminary observations on the use of streptonigrin as an antitumor agent in human beings.

Authors:  W L WILSON; C LABRA; E BARRIST
Journal:  Antibiot Chemother (Northfield)       Date:  1961-03

2.  Clinical observations on the effects of streptonigrin in patients with neoplastic disease.

Authors:  C A HACKETHAL; R B GOLBEY; C T TAN; D A KARNOFSKY; J H BURCHENAL
Journal:  Antibiot Chemother (Northfield)       Date:  1961-03
  2 in total
  3 in total

1.  Analysis of the activities of RAD54, a SWI2/SNF2 protein, using a specific small-molecule inhibitor.

Authors:  Julianna S Deakyne; Fei Huang; Joseph Negri; Nicola Tolliday; Simon Cocklin; Alexander V Mazin
Journal:  J Biol Chem       Date:  2013-09-16       Impact factor: 5.157

2.  Biological assay of streptonigrin (NSC 45383) in body fluids and tissues of mice.

Authors:  R F Pittillo; C Woolley
Journal:  Antimicrob Agents Chemother       Date:  1974-01       Impact factor: 5.191

3.  Renal Cell Carcinoma Is Abrogated by p53 Stabilization through Transglutaminase 2 Inhibition.

Authors:  Seon-Hyeong Lee; Won-Kyu Lee; Nayeon Kim; Joon Hee Kang; Kyung-Hee Kim; Seul-Gi Kim; Jae-Seon Lee; Soohyun Lee; Jongkook Lee; Jungnam Joo; Woo Sun Kwon; Sun Young Rha; Soo-Youl Kim
Journal:  Cancers (Basel)       Date:  2018-11-19       Impact factor: 6.639
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.